ORAL AND INHALED STEROIDS IN CROUP - A RANDOMIZED, PLACEBO-CONTROLLEDTRIAL

Citation
Gc. Geelhoed et Wbg. Macdonald, ORAL AND INHALED STEROIDS IN CROUP - A RANDOMIZED, PLACEBO-CONTROLLEDTRIAL, Pediatric pulmonology, 20(6), 1995, pp. 355-361
Citations number
26
Categorie Soggetti
Respiratory System",Pediatrics
Journal title
ISSN journal
87556863
Volume
20
Issue
6
Year of publication
1995
Pages
355 - 361
Database
ISI
SICI code
8755-6863(1995)20:6<355:OAISIC>2.0.ZU;2-5
Abstract
It was the objective of this study to compare the efficacy of oral dex amethasone and inhaled budesonide in children hospitalized with croup, using a three-way, double blind, randomized, placebo-controlled clini cal trial design. The trial was carried out in the Emergency Departmen t Observation Ward of a tertiary pediatric hospital. The subjects for the study were 80 children (age range 5 to 158 months) who were hospit alized with croup. Children received either 2 mg of nebulised budesoni de, dexamethasone syrup (0.6 mg/kg) or a placebo. Median duration of h ospitalization was shorter for children treated with dexamethasone (12 hr) and budesonide (13 hr) compared to placebo (20 hr) (P < 0.03). Th ere was no significant difference in hospitalization time between chil dren treated with dexamethasone and budesonide. Median time to a croup score of less than or equal to 1 was shorter for children treated wit h dexamethasone (2 hr) or budesonide (3 hr) compared to those who rece ived placebo (8 hr) (P < 0.01). Group scores for both steroid groups w ere significantly lower than the placebo group by 1 hr and remained so subsequently. The croup scores did not differ significantly in the 2 steroid treated groups. Six of the 30 children (20%) in the placebo gr oup required adrenaline after the first hour compared to none of the 5 0 children in the steroid treated groups (P < 0.02). We conclude that oral dexamethasone and inhaled budesonide are both effective in reduci ng symptoms and duration of hospitalization in children with croup. (C ) 1995 Wiley-Liss, Inc.